{"transactions":[{"id":728567,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:29:59.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001700969-26-000002","document":"wk-form4_1782246596.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000170096926000002/wk-form4_1782246596.xml","form_type":"4"}},{"id":1103421,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-24T01:03:12.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001737287-25-000072","document":"wk-form4_1750726985.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000173728725000072/wk-form4_1750726985.xml","form_type":"4"}},{"id":1486055,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-07T21:29:44.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":191082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":191082,"derivative":{"exercise_price":2.44,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":191082},"source":{"system":"sec-edgar","filing":"0001593968-24-000837","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000159396824000837/primary_01.xml","form_type":"4"}},{"id":1853771,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-15T21:00:10.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":74561,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":292832,"source":{"system":"sec-edgar","filing":"0001593968-23-001009","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000159396823001009/primary_01.xml","form_type":"4"}},{"id":2185263,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T21:40:07.000Z","date":"2022-08-12","kind":"sale","acquired":false,"shares":5000,"price":17.25,"value":86250.0,"ownership":{"direct":true},"balance_after":218271,"source":{"system":"sec-edgar","filing":"0001737287-22-000069","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000173728722000069/primary_doc.xml","form_type":"4"}},{"id":2185262,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T21:40:07.000Z","date":"2022-08-11","kind":"sale","acquired":false,"shares":10000,"price":16.5,"value":165000.0,"ownership":{"direct":true},"balance_after":223271,"source":{"system":"sec-edgar","filing":"0001737287-22-000069","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000173728722000069/primary_doc.xml","form_type":"4"}},{"id":2185261,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T21:12:04.000Z","date":"2022-08-12","kind":"sale","acquired":false,"shares":5000,"price":17.25,"value":86250.0,"ownership":{"direct":true},"balance_after":218271,"source":{"system":"sec-edgar","filing":"0001737287-22-000068","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000173728722000068/primary_doc.xml","form_type":"4"}},{"id":2185260,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T21:12:04.000Z","date":"2022-08-11","kind":"sale","acquired":false,"shares":10000,"price":16.5,"value":165000.0,"ownership":{"direct":true},"balance_after":223271,"source":{"system":"sec-edgar","filing":"0001737287-22-000068","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000173728722000068/primary_doc.xml","form_type":"4"}},{"id":2222697,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-23T20:40:49.000Z","date":"2022-06-22","kind":"sale","acquired":false,"shares":10000,"price":11.76,"value":117600.0,"ownership":{"direct":true},"balance_after":233271,"source":{"system":"sec-edgar","filing":"0001214659-22-008272","document":"marketforms-56519.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000121465922008272/marketforms-56519.xml","form_type":"4"}},{"id":2226517,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T20:58:11.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":35535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments."}],"balance_after":35535,"derivative":{"exercise_price":9.62,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":35535},"source":{"system":"sec-edgar","filing":"0001214659-22-008169","document":"marketforms-56490.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000121465922008169/marketforms-56490.xml","form_type":"4"}},{"id":2226516,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-17T20:58:11.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":22089,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":243271,"source":{"system":"sec-edgar","filing":"0001214659-22-008169","document":"marketforms-56490.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000121465922008169/marketforms-56490.xml","form_type":"4"}},{"id":2574333,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-09T21:32:39.000Z","date":"2021-09-09","kind":"sale","acquired":false,"shares":5000,"price":25.54,"value":127700.0,"ownership":{"direct":true},"balance_after":221182,"source":{"system":"sec-edgar","filing":"0001214659-21-009372","document":"marketforms-53760.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000121465921009372/marketforms-53760.xml","form_type":"4"}},{"id":2593235,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-23T20:22:22.000Z","date":"2021-08-20","kind":"sale","acquired":false,"shares":5000,"price":23.24,"value":116200.0,"ownership":{"direct":true},"balance_after":226182,"source":{"system":"sec-edgar","filing":"0001214659-21-008900","document":"marketforms-53642.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000121465921008900/marketforms-53642.xml","form_type":"4"}},{"id":2593234,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-23T20:22:22.000Z","date":"2021-08-20","kind":"sale","acquired":false,"shares":5000,"price":23.7,"value":118500.0,"ownership":{"direct":true},"balance_after":231182,"source":{"system":"sec-edgar","filing":"0001214659-21-008900","document":"marketforms-53642.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000121465921008900/marketforms-53642.xml","form_type":"4"}},{"id":2671273,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-11T21:48:58.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":28015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 12 equal monthly installments beginning July 10, 2021."}],"balance_after":28015,"derivative":{"exercise_price":25.76,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":28015},"source":{"system":"sec-edgar","filing":"0001214659-21-006504","document":"marketforms-53100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000121465921006504/marketforms-53100.xml","form_type":"4"}},{"id":2671272,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-11T21:48:58.000Z","date":"2021-06-09","kind":"sale","acquired":false,"shares":9969,"price":25.05,"value":249723.45,"ownership":{"direct":true},"balance_after":236182,"source":{"system":"sec-edgar","filing":"0001214659-21-006504","document":"marketforms-53100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000121465921006504/marketforms-53100.xml","form_type":"4"}},{"id":3115774,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-09T20:06:03.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":9969,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":246151,"source":{"system":"sec-edgar","filing":"0001214659-20-005496","document":"marketforms-49010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000121465920005496/marketforms-49010.xml","form_type":"4"}},{"id":3479718,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-25T00:00:45.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":26025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 12 equal monthly installments beginning July 6, 2019."}],"balance_after":26025,"derivative":{"exercise_price":25.95,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":26025},"source":{"system":"sec-edgar","filing":"0001209191-19-038862","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000120919119038862/doc4.xml","form_type":"4"}},{"id":3787896,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-10-17T21:32:48.000Z","date":"2018-10-15","kind":"exercise","acquired":false,"shares":7130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Convertible Preferred Stock converted on a 5.25-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Convertible Preferred Stock converted on a 5.25-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Convertible Preferred Stock converted on a 5.25-for-1 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37432},"source":{"system":"sec-edgar","filing":"0001209191-18-055388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000120919118055388/doc4.xml","form_type":"4"}},{"id":3787895,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-17T21:32:48.000Z","date":"2018-10-15","kind":"exercise","acquired":true,"shares":37432,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Convertible Preferred Stock converted on a 5.25-for-1 basis and had no expiration date."}],"balance_after":236182,"source":{"system":"sec-edgar","filing":"0001209191-18-055388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000120919118055388/doc4.xml","form_type":"4"}},{"id":3787894,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-17T21:32:48.000Z","date":"2018-10-15","kind":"purchase","acquired":true,"shares":15000,"price":18,"value":270000.0,"ownership":{"direct":true},"balance_after":198750,"source":{"system":"sec-edgar","filing":"0001209191-18-055388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000120919118055388/doc4.xml","form_type":"4"}},{"id":4190770,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-05T20:19:13.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":8810,"price":88.79,"value":782239.9,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option provided for vesting in 12 equal monthly installments following June 20, 2017."}],"balance_after":0,"derivative":{"exercise_price":91.21,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":8810},"source":{"system":"sec-edgar","filing":"0001209191-17-056225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056225/doc4.xml","form_type":"4"}},{"id":4190769,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-05T20:19:13.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":17130,"price":96.11,"value":1646364.3,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option provided for vesting in 36 equal monthly installments following March 14, 2017."}],"balance_after":0,"derivative":{"exercise_price":83.89,"expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":17130},"source":{"system":"sec-edgar","filing":"0001209191-17-056225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056225/doc4.xml","form_type":"4"}},{"id":4190768,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-05T20:19:13.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":124.91,"value":3747300.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option provided for vesting in 36 equal monthly installments commencing October 3, 2016."}],"balance_after":0,"derivative":{"exercise_price":55.09,"expiration_date":"2026-10-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-17-056225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056225/doc4.xml","form_type":"4"}},{"id":4190767,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-05T20:19:13.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":173.11,"value":1731100.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option provided for vesting in four equal annual installments following June 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":6.89,"expiration_date":"2024-06-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-056225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056225/doc4.xml","form_type":"4"}},{"id":4190766,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-05T20:19:13.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":5715,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a \"Director Restricted Stock Unit\").  Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056225/doc4.xml","form_type":"4"}},{"id":4190765,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-05T20:19:13.000Z","date":"2017-10-03","kind":"other","acquired":false,"shares":58535,"price":180,"value":10536300.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."}],"balance_after":5715,"source":{"system":"sec-edgar","filing":"0001209191-17-056225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056225/doc4.xml","form_type":"4"}},{"id":4190764,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-05T20:19:13.000Z","date":"2017-09-18","kind":"gift","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64250,"source":{"system":"sec-edgar","filing":"0001209191-17-056225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056225/doc4.xml","form_type":"4"}},{"id":4272411,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2017-06-26T19:55:44.000Z","date":"2017-06-23","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":62.44,"expiration_date":"2025-06-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-17-041873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117041873/doc4.xml","form_type":"4"}},{"id":4272410,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-06-26T19:55:44.000Z","date":"2017-06-23","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on June 6, 2014 and vests in four equal annual installments beginning on the first anniversary of the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":6.89,"expiration_date":"2024-06-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-041873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117041873/doc4.xml","form_type":"4"}},{"id":4272409,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-26T19:55:44.000Z","date":"2017-06-26","kind":"sale","acquired":false,"shares":12500,"price":100.6,"value":1257500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.56 to $100.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":76250,"source":{"system":"sec-edgar","filing":"0001209191-17-041873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117041873/doc4.xml","form_type":"4"}},{"id":4272408,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-26T19:55:44.000Z","date":"2017-06-23","kind":"sale","acquired":false,"shares":12500,"price":100,"value":1250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales made on June 23, 2017 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 28, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":88750,"source":{"system":"sec-edgar","filing":"0001209191-17-041873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117041873/doc4.xml","form_type":"4"}},{"id":4272407,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-26T19:55:44.000Z","date":"2017-06-23","kind":"exercise","acquired":true,"shares":2500,"price":62.44,"value":156100.0,"ownership":{"direct":true},"balance_after":101250,"source":{"system":"sec-edgar","filing":"0001209191-17-041873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117041873/doc4.xml","form_type":"4"}},{"id":4272406,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-26T19:55:44.000Z","date":"2017-06-23","kind":"exercise","acquired":true,"shares":10000,"price":6.89,"value":68900.0,"ownership":{"direct":true},"balance_after":98750,"source":{"system":"sec-edgar","filing":"0001209191-17-041873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117041873/doc4.xml","form_type":"4"}},{"id":4274247,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-06-22T14:33:25.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":8810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in 12 successive equal monthly installments following the date of grant."}],"balance_after":8810,"derivative":{"exercise_price":91.21,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":8810},"source":{"system":"sec-edgar","filing":"0001209191-17-041301","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117041301/doc4.xml","form_type":"4"}},{"id":4274246,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-22T14:33:25.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":2410,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":88750,"source":{"system":"sec-edgar","filing":"0001209191-17-041301","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117041301/doc4.xml","form_type":"4"}},{"id":4382017,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-16T17:13:55.000Z","date":"2017-03-14","kind":"grant","acquired":true,"shares":17130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in 36 equal monthly installments on the last day of each month following the date of grant."}],"balance_after":17130,"derivative":{"exercise_price":83.89,"expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":17130},"source":{"system":"sec-edgar","filing":"0001209191-17-021139","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117021139/doc4.xml","form_type":"4"}},{"id":4382016,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-16T17:13:55.000Z","date":"2017-03-14","kind":"grant","acquired":true,"shares":4690,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":86340,"source":{"system":"sec-edgar","filing":"0001209191-17-021139","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117021139/doc4.xml","form_type":"4"}}]}